Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dermatofibrosarcoma Protuberans Clinical Trial

Official title:
Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

n/a

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

NCT number	NCT00243191
Study type	Interventional
Source	Sarcoma Alliance for Research through Collaboration
Contact
Status	Completed
Phase	Phase 2
Start date	May 2006
Completion date	September 2009

See also
Status	Clinical Trial	Phase
Completed	`NCT00084630` - Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans	Phase 2
Completed	`NCT01154452` - Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Phase 1/Phase 2
Completed	`NCT00720174` - Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma	Phase 1
Completed	`NCT03381846` - Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger	N/A
Completed	`NCT00346164` - Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma	Phase 3
Completed	`NCT00659360` - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma	Phase 2